Core Viewpoint - Zenas BioPharma, Inc. is under investigation for potential securities fraud following disappointing results from a clinical trial, which led to significant stock price declines [1][2][3]. Group 1: Company Overview - Zenas BioPharma, Inc. trades on NASDAQ under the ticker ZBIO [1]. - The company recently announced results from the Phase 3 INDIGO trial of obexelimab for Immunoglobulin G4-Related Disease (IgG4-RD) [2]. Group 2: Trial Results and Market Reaction - The trial results were characterized as "positive" by Zenas, but analysts indicated that the drug's efficacy did not meet the necessary threshold for commercial viability [2]. - Following the announcement, Zenas's stock price dropped by $17.89 per share, or 51.86%, closing at $16.61 on January 5, 2026 [2]. - On a subsequent conference call, the CEO expressed disappointment regarding the hazard ratio, which did not meet expectations, resulting in an additional stock price decline of $1.41 per share, or 8.49%, closing at $15.20 on January 6, 2026 [3].

PresentationGood morning, everyone. Welcome to the Zenas Biopharma Conference Call. [Operator Instructions] Be advised that this call is being recorded at the company's request, and a replay will be available in the Investors section of the company's website following the call.Jennifer FoxChief Business Officer & CFO Thank you, operator, and thank you all for joining us to discuss the top line results of our registrational Phase III INDIGO trial for obexelimab for the treatment of immunoglobulin G4-related ...

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Zenas and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On January 5, 2 ...

Key Takeaways ZBIO shares plunged 51.9% on Jan. 5, even after its phase III INDIGO study met the primary endpoint.Obexelimab cut IgG4-RD flare risk by 56% vs. placebo over 52 weeks and met key secondary endpoints.ZBIO plans FDA BLA filing for obexelimab in Q2 2026 and an EMA application in 2H 2026 for IgG4-RD.Zenas BioPharma (ZBIO) announced that the phase III INDIGO study, which evaluated its lead pipeline candidate, obexelimab, for treating patients with immunoglobulin G4-related disease (IgG4-RD), has me ...

Zenas BioPharma (NASDAQ:ZBIO) shares fell more than 50% in the last trading session following the release of Phase 3 results for obexelimab in patients with immunoglobulin G4-related disease (IgG4-RD).While the trial demonstrated a meaningful reduction in flare risk, efficacy metrics fell short of market expectations, triggering a sharp repricing in the stock. However, when viewed through the Adhishthana framework, this decline appears far from surprising. The stock's cyclical positioning had already signal ...

Core Insights - The analysis highlights significant price declines among three companies, emphasizing the volatility in the biotech and technology sectors [1][4][5] Company Summaries Zenas BioPharma Inc. (NASDAQ:ZBIO) - Experienced a -57.30% drop in stock price, falling to $14.73, following the Phase 3 INDIGO trial results for obexelimab despite positive outcomes [1][5] - The market's negative reaction indicates the unpredictable nature of biotech investments [5] Signing Day Sports, Inc. (SGN) - Stock price decreased to $0.51, reflecting a -46.30% change [2] - The company announced an opportunity in AI and HPC infrastructure with BlockchAIn Digital Infrastructure, but competitive pressures and operational challenges may have contributed to the decline [2] Shineco, Inc. (SISI) - Experienced a -37.16% drop, with stock price falling to $0.18 [3] - The company saw a 6.8% decline during mid-day trading, despite a 99% reduction in trading volume, suggesting market competition and regulatory challenges in China's sectors may be impacting its performance [3] Market Trends - The significant price movements among these companies underscore the stock market's volatility, particularly in the biotech and technology sectors [4] - Investors must consider clinical trial outcomes, regulatory decisions, and competitive pressures when making informed decisions in this rapidly changing landscape [4]

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 250 points on Monday.The Dow traded up 1.66% to 49,183.51 while the NASDAQ gained 0.80% to 23,420.85. The S&P 500 also rose, gaining, 0.81% to 6,913.76.Check This Out: Wall Street’s Most Accurate Analysts Weigh In On 3 Industrials Stocks With Over 5% Dividend YieldsLeading and Lagging SectorsEnergy shares gained by 2.9% on Monday.In trading on Monday, utilities stocks dipped by 2.2%.Top HeadlineThe ISM manufactur ...

Zenas BioPharma Inc. (NASDAQ:ZBIO) stock is trading lower on Monday after the company released results from the Phase 3 INDIGO trial of obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD).IgG4-RD is an immune system disorder where the body creates excess IgG4 antibodies, leading to inflammation and dense, tumor-like tissue growths (fibrosis) in multiple organs. Obexelimab met the primary endpoint, demonstrating a highly statistically significant and clinically meaningful 56% reduction in the risk of I ...

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 250 points on Monday.Following the market opening Monday, the Dow traded up 0.54% to 48,641.58 while the NASDAQ gained 0.65% to 23,386.57. The S&P 500 also rose, gaining, 0.63% to 6,901.52.Check This Out: Wall Street’s Most Accurate Analysts Weigh In On 3 Industrials Stocks With Over 5% Dividend YieldsLeading and Lagging SectorsEnergy shares gained by 2.9% on Monday.In trading on Monday, consumer staples stocks dipped by 0.4% ...

Market Overview - U.S. stocks traded higher, with the Dow Jones index gaining over 250 points, up 0.54% to 48,641.58, NASDAQ up 0.65% to 23,386.57, and S&P 500 up 0.63% to 6,901.52 [1] - Energy shares increased by 2.9% on Monday [1] Sector Performance - Consumer staples stocks dipped by 0.4% [2] Commodity Prices - Oil traded up 1.4% to $58.12, gold up 2.4% to $4,433.50, silver up 7.5% to $76.320, and copper rose 4.1% to $5.9260 [5] European Market Performance - Eurozone's STOXX 600 gained 0.5%, Spain's IBEX 35 Index rose 0.3%, London's FTSE 100 up 0.4%, Germany's DAX gained 0.2%, and France's CAC 40 climbed 0.1% [6] Asian Market Performance - Asian markets closed mostly higher, with Japan's Nikkei 225 gaining 2.97%, Hong Kong's Hang Seng Index up 0.03%, China's Shanghai Composite surging 1.38%, while India's BSE Sensex fell 0.38% [7] Company News - The FDA lifted the clinical hold on GH Research Plc's Investigational New Drug Application for GH001 [3] - Momentus Inc shares surged 94% to $11.14 after announcing the development of an additive-manufactured fuel tank [9] - TMD Energy Ltd shares increased by 76% to $0.78 [9] - VerifyMe Inc shares rose 40% to $0.94 following a strategic merger announcement [9] - Zenas Biopharma Inc shares dropped 55% to $15.54 after Phase 3 trial results [9] - Signing Day Sports Inc shares fell 37% to $0.60, and Lavoro Ltd shares decreased by 26% to $0.82 [9]